21.20
+0.95%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Formosa Pharmaceuticals
Its shares trade on Taiwan Stock Exchange under the ticker 6838.TW. It has been listed since 7 October 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 9.5m and a net loss of TWD 83.6m. At that date it held total assets of TWD 2.07bn and shareholders' equity of TWD 1.46bn.
Formosa Pharmaceuticals, Inc. engages in the research, development, and distribution of new medicine. The company is headquartered in Taipei City, Taipei. The company went IPO on 2021-10-07. The firm also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Oct 2021
- Website
- formosapharma.com ↗
Leadership
Pay as last reported
- Zhengyu ChengChairman of the Board, since 2023
- Like XuChief Executive Officer, General Manager, since 2023
- Jingcheng WeiChief Commercial & Strategic Officer
- Naixian CaoHead of Finance & Accounting, Corporate Governance Officer
- Wenhong HuangDirector
- Mr. Dejun KongDirector
- Hai-I ShenDirector
- Yingxin ZhangDirector
- Zhaozhou KangIndependent Director
- Lizhu LuoIndependent Director
- Ms. Yu-Hui SuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Formosa Pharmaceuticals focuses on innovative pharmaceutical research and development in Taipei City.
- The company's ophthalmic drug APP13007 is in phase III clinical trials for postoperative inflammation treatment.
- TSY-0110 is in preclinical development for breast cancer treatment using antibody-drug conjugate technology.
Weaknesses
- Formosa Pharmaceuticals has not yet commercialized its nanotechnology platform for pharmaceutical dosage forms.
- The company's R&D projects are still in early stages with no approved products on the market.
- Formosa Pharmaceuticals faces challenges in scaling up its patented nano platform for broader applications.
Opportunities
- The global pharmaceutical market offers growth opportunities for Formosa Pharmaceuticals' innovative drugs.
- Formosa Pharmaceuticals can expand its R&D focus to include more anti-cancer therapies like MPT0E028.
- The company can leverage its nanotechnology platform to develop new drug delivery systems for improved bioavailability.
Threats
- Formosa Pharmaceuticals faces competition from established pharmaceutical companies in the Health Care sector.
- The company's reliance on clinical trial success for its pipeline drugs poses a significant risk.
- Regulatory hurdles in Taiwan and international markets could delay product approvals for Formosa Pharmaceuticals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.